Starling Oncology, Inc. (STLN) Reports Q3 Loss, Beats Revenue Estimates
Starling Oncology, Inc. (STLN) delivered earnings and revenue surprises of -85.71% and +0.93%, respectively, for the quarter ...
Model output · Signal date 2026-11-06
Starling Oncology, Inc. (STLN) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
Unlock rating and forecasts
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
of 5150 stocks scored
Rank correlation · 90D
27.0%
Spearman, 357 dates
Market Cap
$356M
small-cap · #4 of 8 peers
Summary
Starling Oncology, Inc. (STLN) stock forecast summary
Our AI scores Starling Oncology, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Starling Oncology, Inc. is a small-cap company with a market capitalization of $356M. It ranks number 4 by market capitalization among the 8 Services-Offices & Clinics of Doctors of Medicine issuers in our coverage with a current forecast.
For STLN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 27.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 30.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, STLN included.
Price
STLN price chart and AI forecast
Cross-section · 2026-11-06
How STLN ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-09-30
Starling Oncology, Inc. (STLN) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Offices & Clinics of Doctors of Medicine peers listed below that report each metric.
Valuation & Market
| Metric | STLN | Rank |
|---|---|---|
| Market Cap | $356M | 4/8 |
| EPS | $-0.53 | – |
| Revenue/Share | $6.31 | – |
| FCF/Share | $0.19 | – |
Profitability & Margins
| Metric | STLN | Rank |
|---|---|---|
| ROA | -18.9% | 5/7 |
| ROIC | -32.8% | 7/8 |
| Operating Margin | -3.4% | 2/8 |
| Net Margin | -5.7% | 3/7 |
| EBT Margin | -5.7% | 2/8 |
| Tax Rate | 0.0% | – |
Financial Health
| Metric | STLN | Rank |
|---|---|---|
| Current Ratio | 1.11x | 2/8 |
| Quick Ratio | 0.82x | 5/6 |
| Interest Coverage | -1.6x | 3/8 |
| Working Capital | $14M | 2/8 |
Cash Flow
| Metric | STLN | Rank |
|---|---|---|
| Operating Cash Flow | $23M | 4/8 |
| Free Cash Flow | $19M | 4/6 |
| Capital Spending | -$4M | 4/6 |
| FCF/Sales | 3.0% | 3/6 |
| CapEx/Sales | 0.7% | 2/6 |
Operational Efficiency
| Metric | STLN | Rank |
|---|---|---|
| Asset Turnover | 3.30x | 1/7 |
| Receivables Turnover | 10.2x | – |
| Fixed Assets Turnover | 58.6x | 3/6 |
| Days Sales Outstanding | 36 days | – |
Income Statement
| Metric | STLN | Rank |
|---|---|---|
| Total Revenue | $620M | 3/7 |
| Operating Income | -$21M | 5/8 |
| Net Income | -$36M | 6/7 |
| SG&A Expense | $118M | 3/7 |
Dividend & Shareholder Information
| Metric | STLN | Rank |
|---|---|---|
| Shares Outstanding | 98M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $138M | 73.3% of assets |
| Cash & Short-term Investments | $37M | 19.7% of assets |
| Accounts Receivable | $61M | 32.3% of assets |
| Inventory | $37M | 19.5% of assets |
| Total Liabilities | $225M | |
| Short-term Debt | $42M | 22.2% of assets |
Quarterly Financial Reports
STLN quarterly financials and insider trading
Industry Peers · Services-Offices & Clinics of Doctors of Medicine
Starling Oncology, Inc. (STLN) industry peers
Companies classified under the same SEC industry code as Starling Oncology, Inc. (Services-Offices & Clinics of Doctors of Medicine): 8 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| STLN Starling Oncology, Inc. | $356M | |
| HIMS Hims & Hers Health, Inc. | $5.92B | |
| TDOC Teladoc Health, Inc. | $1.60B | |
| SBC Sbc Medical Group Holdings Inc | $518M | |
| LFMD Lifemd, Inc. | $110M | |
| AIRS Airsculpt Technologies, Inc. | $38M | |
| HLYK Healthlynked Corp | $5M | |
| CDIX Cardiff Lexington Corp | $110K |
Where STLN sits on the market map
Industrial Applications and Services · Services-Offices & Clinics of Doctors of Medicine
News
Starling Oncology, Inc. (STLN) stock news
Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance
CERRITOS, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, ...
Starling Oncology, Inc. (STLN) Q2 2026 Earnings Call Transcript
Please note this call is being recorded. It is now my pleasure to turn the meeting over to Minh Merchant. Please go ahead. Thank you, operator, and good afternoon, everyone. Welcome to Starling ...
FAQ
Starling Oncology, Inc. (STLN) stock forecast FAQ
What is the Starling Oncology, Inc. (STLN) stock forecast?
Our AI scores Starling Oncology, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Starling Oncology, Inc. stock predictions?
For STLN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 27.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 30.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Starling Oncology, Inc. forecasts updated?
Starling Oncology, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Starling Oncology, Inc.'s industry peers?
8 issuers in our coverage, STLN included, share the SEC industry code Services-Offices & Clinics of Doctors of Medicine. The largest are: Hims & Hers Health, Inc. (HIMS), Teladoc Health, Inc. (TDOC), Sbc Medical Group Holdings Inc (SBC), Lifemd, Inc. (LFMD), Airsculpt Technologies, Inc. (AIRS), Healthlynked Corp (HLYK).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.